| Literature DB >> 31194838 |
Ping-Hsun Wu1,2, Ming-Yen Lin1,3,4, Teng-Hui Huang1, Yi-Ting Lin2,5,6, Chi-Chih Hung1,3, Yi-Chun Yeh7,8, Hung-Tien Kuo1,3, Yi-Wen Chiu1,3, Shang-Jyh Hwang1,3, Jer-Chia Tsai1,3, Juan-Jesus Carrero9.
Abstract
BACKGROUND: Depression is common in dialysis patients, but the clinical impact of this condition is poorly defined.Entities:
Mesh:
Year: 2019 PMID: 31194838 PMCID: PMC6564035 DOI: 10.1371/journal.pone.0218335
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Patient selection flow chart.
Baseline characteristics among dialysis patients with and without depression.
| Depression | Controls | ||
|---|---|---|---|
| (n = 2,475) | (n = 12,375) | ||
| Characteristic | N (%) | N (%) | |
| 62.6 ± 12.3 | 62.6 ± 12.3 | 0.9 | |
| >0.99 | |||
| 18–39 years | 109 (4.4%) | 545 (4.4%) | |
| 40–59 years | 870 (35.2%) | 4,350 (35.2%) | |
| 60–85 years | 1,496 (60.4%) | 7,480 (60.4%) | |
| >0.99 | |||
| Men | 901 (36.4%) | 4,505 (36.4%) | |
| Women | 1,574 (63.6%) | 7,870 (63.6%) | |
| 0. 4 | |||
| Haemodialysis | 2,326 (94.0%) | 11,570 (93.5%) | |
| Peritoneal dialysis | 149 (6.0%) | 805 (6.5%) | |
| 0.7 | |||
| City area | 1,773 (71.7%) | 8,824 (71.4%) | |
| Rural area | 699 (28.3%) | 3,531 (28.6%) | |
| 0.02 | |||
| Low | 944 (38.1%) | 4,638 (37.5%) | |
| Moderate | 1,088 (44.0%) | 5,226 (42.2%) | |
| High | 443 (17.9%) | 2,511 (20.3%) | |
| Diabetes mellitus | 1,355 (54.7%) | 6,343 (51.3%) | 0.002 |
| Hypertension | 2,086 (84.3%) | 10,082 (81.5%) | 0.001 |
| Hyperlipidaemia | 587 (23.7%) | 2,504 (20.2%) | <0.001 |
| Coronary artery disease | 747 (30.2%) | 3,077 (24.9%) | <0.001 |
| Heart failure | 660 (26.7%) | 3,298 (26.7%) | >0.99 |
| Cerebrovascular disease | 548 (22.1%) | 1,481 (12.0%) | <0.001 |
| Autoimmune disease | 61 (2.5%) | 231 (1.9%) | 0.06 |
| Malignancy | 207 (8.4%) | 845 (6.8%) | 0.007 |
| Alcohol dependence | 23 (0.9%) | 86 (0.7%) | 0.3 |
| Psychotic disorder | 76 (3.1%) | 62 (0.5%) | <0.001 |
| Anxiety disorder | 375 (15.2%) | 407 (3.3%) | <0.001 |
| Sleep disorder | 660 (26.7%) | 1,214 (9.8%) | <0.001 |
| Antiplatelets/Warfarin | 1,143 (46.2%) | 5,697 (46.0%) | 0.9 |
| Anti-hypertensive drugs | 1,880 (76.0%) | 9,224 (74.5%) | 0.1 |
| Statins | 757 (30.6%) | 3,735 (30.2%) | 0.7 |
| Oral antidiabetic agents | 791 (32.0%) | 3,739 (30.2%) | 0.09 |
| Insulin | 667 (26.9%) | 2,967 (24.0%) | 0.002 |
| Antipsychotic agents | 761 (30.7%) | 1,798 (14.5%) | <0.001 |
| Benzodiazepines | 1,480 (59.8%) | 5,399 (43.6%) | <0.001 |
| Hypnotics | 1,506 (60.8%) | 4,935 (39.9%) | <0.001 |
| <0.001 | |||
| 2000–2003 | 1,025 (41.4%) | 5,667 (45.8%) | |
| 2004–2007 | 1,450 (58.6%) | 6,708 (54.2%) | |
| Mean ± SD | 3.2 ± 2.1 | 3.6 ± 2.2 | <0.001 |
| Median (IQR) | 2.7 (1.5–4.6) | 3.1 (1.7–5.1) | <0.001 |
Fig 2Cumulative incidence of (A) death and (B) major cardiovascular events in incident dialysis patients with vs without depression. For the cumulative incidence of major cardiovascular events, Fine-Gray methods were performed accounting for the competing risk of death.
Clinical outcomes associated with depression among incident dialysis patients.
| Variable | Overall events (Depression/Control) | Adjusted Hazard Ratio (95% CI) | ||
|---|---|---|---|---|
| Event numbers | Incidence rate | Model 1 | Model 2 | |
| 1,121 / 4,890 | 142.22 / 111.28 | 1.15 (1.07–1.23) | 1.24 (1.16–1.33) | |
| 806 / 3,787 | 94.07 / 81.73 | 1.03 (0.95–1.12) | 1.03 (0.95–1.12) | |
| 1,140 / 4,990 | 152.06 / 117.04 | 1.16 (1.08–1.24) | 1.14 (1.06–1.22) | |
| 513 / 2,100 | 52.06 / 39.4 | 1.19 (1.08–1.32) | 1.22 (1.09–1.35) | |
MACE defined as the composite of acute coronary syndrome, heart failure, ischemic stroke, and hemorrhagic stroke.
†Model 1: Adjusted for comorbid disorders (diabetes mellitus, hypertension, hyperlipidaemia, coronary artery disease, cerebrovascular disease, autoimmune disease, malignancy, alcohol dependence, psychotic disorder, anxiety disorder, sleep disorder), and competing risk of death (when appropriate).
‡Model 2: Adjusted for comorbid disorders, medications (antiplatelets/warfarin, anti-hypertensive drugs, statins, oral antidiabetic agents, insulin, antipsychotic agents, benzodiazepines, hypnotics), and competing risk of mortality
§ Analyses predicting death and fatal infections used Cox-proportional hazard models; Analyses predicting MACE or severe infections used Fine and Gray models accounting for the competing risk of death.
#Incident rate (per 1000 person-years)
*p<0.05
**p<0.01
***p<0.001
Fig 3Cumulative incidence of (A) severe infections and (B) fatal infections in incident dialysis patients with vs without depression. For the cumulative incidences of severe infections, Fine-Gray methods were performed accounting for the competing risk of death.
Fig 4Risks of single infection events associated with clinical depression.
Footnote: Subdistribution hazard Model: Adjusted for comorbid disorders (diabetes mellitus, hypertension, hyperlipidaemia, coronary artery disease, cerebrovascular disease, autoimmune disease, malignancy, alcohol dependence, psychotic disorder, anxiety disorder, sleep disorder), medications (antiplatelets/warfarin, anti-hypertensive drugs, statins, oral antidiabetic agents, insulin, antipsychotic agents, benzodiazepines, hypnotics), and competing risk of mortality *p<0.05, **p<0.01, ***p<0.001.